RxDoctor Payments Data

Rory Panepinto, MD

Podiatrist · Metairie, LANPI 1427003284

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,658 of the $11,881 with a category attached, or 64.5%. 40 manufacturers reported payments, led by Anika Therapeutics, Inc. at 26.9% of the total. Reporting peaked in 2021 at $4,313 and has fallen 61.2% since, to $1,672 in 2025. Among podiatrist clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,881in general payments, 2019–2025

Across 302 payments — averaging $39.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Anika Therapeutics, Inc.$3K
  • Smith+Nephew$1K
  • Vilex LLC$1K
  • Amgen$830
  • Paratek Pharmaceuticals, Inc.$607
  • Stryker$489
  • plus $4K from 34 others

What the payments were for

  • Consulting fees$2,00017%
  • Travel & lodging$2,21319%
  • Food & beverage$7,65864%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,881 in reported general payments places this provider in the 90th percentile of 68 podiatrist providers in Louisiana.

See all podiatrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$152,888
Medicare patients
426
Services billed
2,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole228$5,442
Terbinafine Hcl89$1,063
Colchicine23$846
Lidocaine-PrilocaineLidocaine/Prilocaine13$798
Doxycycline Hyclate69$660
Cephalexin54$439
Fluconazole13$405
Gabapentin24$390
Ibuprofen45$332
Amoxicillin58$312
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen27$225
Clindamycin Hcl15$156
Levofloxacin34$139
Methylprednisolone12$101
Promethazine Hcl24$99

Paid to pharmacies, not to this prescriber.

Other podiatrist in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →